Suppr超能文献

伊朗的胰腺癌-伊朗国家癌症登记计划的结果。

Pancreatic Cancer in Iran - Result of the Iranian National Cancer Registry Program.

机构信息

Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran.

出版信息

Asian Pac J Cancer Prev. 2022 Nov 1;23(11):3825-3831. doi: 10.31557/APJCP.2022.23.11.3825.

Abstract

OBJECTIVE

In this article, we aimed to report the incidence rate of PC at the national and regional levels of Iran from 2014 to 2017 for the first time based on the IARC protocols.

METHODS

The data was recruited from the Iranian national program of cancer registry, a national cancer registry program reformed in 2014 after including cancer diagnosis based on clinical judgment and death certificates. This registry includes data from the pathology laboratories and clinical sectors included with death certificates from 60 medical universities in 31 provinces of Iran. Age-standardized incidence rates were calculated at the national and regional levels.

RESULTS

From 2014 to 2017, 8851 new cases (males=60.46%) were diagnosed, with a mean age of 66.2 ± 19.6. Forty-one percent of the patients were diagnosed by microscopic verification, and 51% were diagnosed based on clinical judgment without microscopic verification and death certificates. The age-standardized incidence rate was measured as 3.45 per 100,000 in 2017, with the highest rates in individuals older than 85 (30.91 per 100,000), and the provinces of Qom, Tehran, and Isfahan recorded the highest incidence rates with 3.87, 3.85, and 3.66 per 100,000 respectively.

CONCLUSIONS

PC incidence in Iran is still lower than in western countries. However, the incidence from 2014 to 2017 is higher than previous national and regional reports and should not be overlooked. Improvement in the national cancer registry program and documentation may be reasons for this difference.

摘要

目的

本文首次根据国际癌症研究机构(IARC)的方案,报告 2014 年至 2017 年伊朗全国和地区前列腺癌(PC)的发病率。

方法

数据来自伊朗国家癌症登记处,这是一个国家癌症登记处项目,于 2014 年进行了改革,纳入了基于临床判断和死亡证明的癌症诊断。该登记处包括来自伊朗 31 个省份 60 所医科大学的病理实验室和临床部门的数据,包括死亡证明。在国家和地区层面计算了年龄标准化发病率。

结果

2014 年至 2017 年,诊断出 8851 例新病例(男性占 60.46%),平均年龄为 66.2 ± 19.6 岁。41%的患者通过显微镜验证诊断,51%的患者通过临床判断且无显微镜验证和死亡证明诊断。2017 年年龄标准化发病率为每 10 万人 3.45 例,85 岁以上人群发病率最高(每 10 万人 30.91 例),库姆、德黑兰和伊斯法罕省的发病率最高,分别为每 10 万人 3.87、3.85 和 3.66 例。

结论

伊朗的 PC 发病率仍低于西方国家。然而,2014 年至 2017 年的发病率高于之前的全国和地区报告,不容忽视。国家癌症登记处项目和文件记录的改善可能是造成这种差异的原因。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/020a/9930944/50edbb50a933/APJCP-23-3825-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验